FLT3 defines a promising target for the treatment of acute myeloid leukemia (AML). In contrast to their efficacy in cell lines, FLT3-specific inhibitors as single agents have only modest clinical activity in patients with AML. As demonstrated here, overexpression of anti-apoptotic proteins of the BCL2 family leads to resistance against FLT3 inhibitors in a hematopoietic cell line model with activating FLT3 mutations. The susceptibility to FLT3 inhibition could be restored by treatment with the novel BH3 mimetic ABT-737. Primary AML samples tested in our study showed a high expression of BCL2 protein, but not of BCL-xL or MCL1. BCL2 protein levels were not reduced after dephosphorylation of FLT3 and its downstream target STAT5 in patient samples with FLT3 internal tandem duplications. Interestingly, treatment with ABT-737 caused apoptotic cell death in all primary AML samples at submicromolar level and synergized efficiently with FLT3 inhibition in AML samples with activating FLT3 mutations. In contrast to AML cell lines, BCR-ABL transformed human cells showed resistance to ABT-737, which might be due to the induction of MCL1 by BCR-ABL. Inhibition of BCL2 family members might define a novel highly efficient and specific strategy in the combined or monotreatment of AML.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous malignant disease, which is currently treated with chemotherapeutic agents or bone marrow transplantation. Exploiting the growing insights in specific molecular targets that are essential for the survival of the leukemic clone might facilitate the establishment of novel therapeutic regimens and the reduction of unspecific toxicity related to conventional chemotherapy. 1, 2 The FLT3 receptor tyrosine kinase is among the most attractive targets for the treatment of AML, since activating mutations of FLT3 occur frequently in this disease and are associated with impaired survival of the related patients. [3] [4] [5] [6] Internal tandem duplications of the FLT3 receptor (FLT3-ITD, also referred to as FLT3 length mutations, FLT3-LMs) lead to constitutive phosphorylation of FLT3 and its downstream target STAT5 and induce transformation in hematopoietic cells. 7, 8 A recent study has demonstrated that FLT3-ITDs are present in immature CD34
þ /CD33 À progenitor cells from AML samples underlining the importance of these mutations for the molecular pathogenesis of AML. 9 The success of the small molecule inhibitor imatinib in the treatment of chronic myeloid leukemia (CML) has prompted the development and clinical evaluation of protein tyrosine kinase (PTK) inhibitors selective for FLT3. [10] [11] [12] Cytotoxicity in primary AML blasts and clinical response has been reported to be highly heterogeneous despite the ability of FLT3 inhibitors to completely dephosphorylate the mutated and wild-type (WT) FLT3 receptor. 13, 14 The molecular reasons for this heterogeneity remain elusive and are of great importance for all AML patients whose blast cells express activated FLT3 receptor.
In this study, we have identified BCL2 protein expression as an important factor that might, at least in part, explain the limited clinical efficacy of FLT3 inhibitors in the treatment of FLT3-positive AML. Inhibition of BCL2 activity by novel compounds might pave the way for innovative and effective therapy regimens in acute leukemias.
Materials and methods

Primary samples
Patient samples used in this study were recruited into the German AMLCG trials and referred to the Laboratory for Leukemia Diagnostics between 2002 and 2006. All patients were newly diagnosed and the derived samples underwent a standardized processing including central sample registration, preparation and evaluation by cytomorphology, cytochemistry, multiparameter immunophenotyping, cytogenetics, fluorescence in situ hybridization and molecular genetics. The study abides by the rules of the local internal review board and the tenets of the revised Helsinki protocol. If possible, mononuclear cells derived from patient samples were used directly after taking of blood samples and Ficoll-Histopaque density gradient centrifugation. Primary cells and cell lines were cultured at 371C with 5% CO 2 in RPMI-1640 medium supplemented with 10% (cell lines) or 20% (primary cells) fetal bovine serum (FBS) and penicillin/streptomycin as described previously. 12 Analysis of apoptosis in primary patient samples by flow cytometry (Nunc, Wiesbaden, Germany). After incubation for 24 h, the cells were stained with Annexin V-PE and 7-AAD according to the manufacturer's instructions (Becton Dickinson, Heidelberg, Germany) and subjected to flow cytometry. Samples that showed cell viability below 50% as assessed for untreated samples after 24 h of culture were not analyzed further for apoptotic cell death caused by inhibitor treatment. Peripheral blood mononuclear cells (PBMNC) of healthy donors were used directly after isolation. In the cases indicated, PBMNC were stimulated with phytohemagglutinin-L (PHA; Roche, Mannheim, Germany) for 4 days as recommended by the manufacturer's instructions and used for analyses of apoptotic cell death or protein expression. The presenting features of all patients and healthy donors from whom primary cells were obtained are summarized in Table 1 .
For combination experiments in primary AML samples to assess the cytotoxicity of combined FLT3 and BCL2 inhibition, cells were again thoroughly thawed by dropwise addition of prewarmed medium. Clumping was prevented using DNAse I (CellSystems GmbH, St Katharinen, Germany) as recommended by the manufacturer's instructions and subsequent filtering. The cells were supplemented with 10 ng/ml G-CSF (ImmunoTools, Friesoythe, Germany) and cultured for 72 h with increasing doses of SU5614 or Sunitinib, respectively, and for 48 h with ABT-737 at a concentration of 0, 0.01 or 0.025 mM. Determination of combination indices (Ci) after Chou and Talay for different concentrations of ABT-737 was performed as described before. 15, 16 A Ci less than 1 indicates synergy, a value higher than 1 indicates antagonism, and a value of 1 indicates an additive effect.
Clonogenic assays were performed as described elsewhere.
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Reagents and plasmids
The small molecule BH3 mimetic ABT-737 and the enantiomer of ABT-737 with low binding affinity to BCL2 family proteins (ABT control substance, ABT-CTRL) were kindly provided by Abbott Laboratories (Abbott Park, IL, USA). 18 SU5614 and MG-132 were purchased from Calbiochem (Bad Soden, Germany). Sunitinib maleate was purchased from Sequoia Research (Pangbourne, UK). All inhibitors were dissolved at a concentration of 10 mM in dimethylsulfoxide (DMSO).
Full-length human cDNA for BCL2 was provided by Dr Zhongwei Xu, 19 and BCL-xL by Dr Stanley Korsmeyer's lab (Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA).
Transduction of Ba/F3 cells, cell proliferation and western blotting
Transduction of IL-3-dependent Ba/F3 cells and cell proliferation assays of Ba/F3 and human leukemic cell lines were performed as described previously. 12, 20 Stable protein expression after transduction and fluorescence-activated cell sorting (FACS) was confirmed by western blotting. Analysis of total cell lysates and immunoprecipitation were performed as described previously, 21 
Statistical analysis
Data were statistically analyzed using two-sided t-test (Excel; Microsoft, Redmond, WA, USA). Differences with a P-value below 0.05 were considered statistically significant. 12 In the study presented here, treatment of primary AML blasts with SU5614 led to dephosphorylation of FLT3 receptor and its essential downstream target STAT5 in vitro when sufficiently high concentrations of the inhibitor (10 mM) were used ( Figure 1a) . As it has been described elsewhere, 13 however, dephosphorylation of FLT3 does not necessarily induce cytotoxicity in AML blasts derived from patient samples. In our study, only modest cytotoxicity was observed in primary AML samples, when SU5614 was used in monotreatment ( Figure 6d , data not shown). Using the more water-soluble derivative Sunitinib (SU11248), the IC 50 could be reached in the tested samples, but it was far above the IC 50 values observed for FLT3-ITD positive cell lines MOLM-13 and MV4-11 (median: 0.018 vs 0.73 mM in patient samples). As we could show before, 22 overexpression of anti-apoptotic proteins such as BCL-xL renders FLT3-transformed Ba/F3 cells resistant to cytotoxicity caused by FLT3 inhibitors if these proteins are expressed independently from FLT3. Thus, we speculated that antiapoptotic proteins of the BCL2 family might add to the resistance of primary AML cells against FLT3 inhibition. The expression of BCL2 and BCL-xL in primary patient samples was analyzed as shown for one representative western blot (Figure 1b ). Presenting features of patient samples included are summarized in the Table 1 . The majority of patients carried activating FLT3 mutations and showed a normal karyotype. Interestingly, we did not only obtain a distinct signal of BCL2 protein in all AML samples tested, but also an increased expression compared to samples that were derived from PBMNC of three healthy donors. Total cell lysates from HEK-293 (E), K562 (K) and HL-60 (H) cell lines served as positive and negative controls, respectively. The results obtained by immunoblotting were analyzed densitometrically ( Figure 1e ). Signal intensity was normalized to protein content in the samples as measured by signal intensity of the structure protein b-Actin. All values are displayed in relation to the ratio found in HEK-293 cells that was arbitrarily set to 1. From these experiments, we could conclude that BCL2 was expressed at a high level in AML samples compared to normal PBMNC. Overall, there was a median 3-fold (range 2.3-to 3.8-fold) increase for BCL2 protein that was statistically significant (Po0.001, two-sided t-test). Conversely, BCL-xL showed no statistically significant elevation in signal intensity (median 1.42-fold, range 0.82-to 1.9-fold). The expression of BCL-xL was modestly elevated for AML samples with FLT3-ITD in comparison with the remaining samples (in median 1.64-fold increase compared to PBMNC for samples with FLT3-ITD and in median 1.16-fold for the remaining samples), but the difference was not statistically significant (P ¼ 0.080, two-sided t-test).
A high expression of BCL2 and BCL-xL could also be detected in two acute lymphoblastic leukemia (ALL) samples with translocation, 9, 22 but not in a sample from a patient with CML that was available for this study.
To test whether the increased expression of BCL2 was dependent on the activity and phosphorylation status of the FLT3 receptor, we performed immunoblotting to determine the level of BCL2 after prolonged treatment with FLT3 inhibitor (36 h). As shown in Figure 1a , no decrease in BCL2 expression was observed. Essentially the same results were obtained for AML #3 and #4. These findings indicate that BCL2 might play a prominent role in resistance to chemotherapy and molecular therapeutics in acute leukemias.
ABT-737 restores response to FLT3 inhibitor treatment in a hematopoietic cell line model of AML
To confirm further this hypothesis, we tested the novel small molecule inhibitor ABT-737 in a modified in vitro cell line model of FLT3 positive AML. ABT-737 has been described to disrupt efficiently intracellular BCL2 family interactions by binding to the hydrophobic BH3 groove of these proteins. 18 It binds with high affinity to BCL2, BCL-xL and BCL-w, but not to the less homologous protein MCL1.
We and others have reported that IL-3-dependent Ba/F3 cells can be transformed by constitutively activated FLT3 receptor. 8, 12 Since we could demonstrate that BCL2 is expressed independently from the activity of FLT3 (Figure 1a ), we used a Ba/F3 cell line model in which BCL2 or BCL-xL, respectively, were stably expressed ectopically from a different plasmid that was co- ABT-737 neutralizes resistance to FLT3 inhibitor treatment in primary AML samples TM Kohl et al transfected with FLT3-ITD in a modified pMSCV vector. Thus, dephosphorylation of FLT3 receptor could not result in downregulation of BCL2 in these cells mimicking the situation in primary AML blasts as described above (see also Figure 7 ). Ba/F3 cells carrying FLT3-ITD that were concomitantly transduced with BCL2 or BCL-xL, respectively, showed marked resistance to apoptotic cell death caused by SU5614 in contrast to mocktransduced Ba/F3-FLT3-ITD cells (Figure 2a) . The combination of SU5614 and ABT-737 was able to overcome the observed resistance (Figures 2b and c) and resulted in apoptotic cell death which was induced at very low concentrations of ABT-737 for Ba/F3 cells stably expressing FLT3-ITD and BCL2 (IC 50 ¼ 0.1 mM) and at higher concentrations for cells concomitantly expressing FLT3-ITD and BCL-xL (IC 50 ¼ 1.0 mM). To confirm the specificity of ABT-737, we included the enantiomer of ABT-737 as a lossof-function control in all our experiments (ABT-CTRL or CTRL). As shown in Supplementary Figure S1 , ABT-737 and ABT-CTRL did not cause significant cytotoxicity in Ba/F3 cells when used in mono-treatment.
We next analyzed the ability of ABT-737 to induce cleavage of Caspase-3 as a measure of apoptotic cell death (Figure 2d ). Untreated cells showed a low background level of cleaved products that had a molecular weight of 17 and 19 kDa. SU5614 mono-treatment induced cleavage in mock-transduced FLT3-ITD cells only, whereas all cell lines treated with ABT-737, but not with ABT-CTRL, showed increased levels of cleaved Caspase-3. The highest activation was shown for the combined treatment with SU5614 and ABT-737.
ABT-737 induces apoptosis in AML cells lines, but not in BCR-ABL positive cells
In order to confirm these results in human cell lines, we tested a panel of cell lines derived from CML (K-562, KCL-22), ALL (SD-1) and AML patients (HL-60, Kasumi-1, MV4-11, MOLM-13) for susceptibility to ABT-737 (Figure 3a) . Two of these cell lines have been described to carry FLT3 LMs (MV4-11 and MOLM-13). In all AML cell lines, substantial levels of BCL2 were detected (Figure 3b ) and all four responded to ABT-737 at submicromolar concentrations (summarized in Figure 3a) . HL-60, MV4-11 and MOLM-13 cell lines contained very high expression levels of BCL2 that were comparable to HEK-293 cells transfected with cDNA for human BCL2 subcloned in a pMSCV vector under the control of a retroviral promoter. In contrast, expression levels of BCL-xL were low (MV4-11) or almost undetectable (HL-60, Kasumi-1, MOLM-13).
Again, we found that the activity of ABT-737 depended on the activation of caspase-3 ( Figure 3c ): cleaved caspase-3 could be detected in MOLM-13 cells after 4 h treatment with ABT-737 (0.1 mM), but not with Cytarabine (AraC, 1.0 mM).
Interestingly, all cell lines carrying the Philadelphia chromosome (Ph þ ) were found to be resistant to ABT-737 up to very high concentrations (Figure 3a) . The IC 50 values determined for K-562 and KCL-22 cells were about 40-fold higher in comparison to the median IC 50 of the four susceptible AML cell lines tested (53 nM) and about 16-fold higher for the SD-1 cell line. ABT-737 treatment did not cause significant activation of caspase-3 in KCL-22 cells (Figure 3c ). To identify the ABT-737 neutralizes resistance to FLT3 inhibitor treatment in primary AML samples TM Kohl et al underlying mechanism for the resistance of these cell lines to ABT-737 we examined the expression level of the BCL2 family member MCL1 which is a known downstream target of BCR-ABL. 23 MCL1 might be able to counteract BCL2 and BCL-xL inhibition since it has been shown to form heterodimers with both BAX and BAK via its BH3 domain 24, 25 and inhibits the activation of these proteins in HeLa cells. 25 We could detect a high expression of MCL1 in the Ph þ cell lines as well as in native HEK-293 cells (Figure 3b ), but not in the AML cell lines susceptible to BCL2 inhibition.
Inhibition of BCL2 specifically induces apoptosis in primary AML blasts
Since we identified BCL2 as an important regulator of cellular drug resistance in primary AML samples (Figure 1) we investigated whether inhibition of BCL2 might induce apoptotic cell death in AML blasts from primary patient samples in vitro. Figures 4a and c show the results of treatment with increasing concentrations of ABT-737 and ABT-CTRL in AML sample #1 and #2, respectively, for 24 h and two representative dot plots are given in Figures 4b and d. Figure 4e summarizes the results of AML samples that were available for testing. All samples efficiently underwent apoptotic cell death with IC 50 values in the submicromolar range that were comparable to the results in human AML cell lines (Figure 3a) , whereas the loss-of-function control (ABT-CTRL) was drastically less efficient. To compensate for the heterogeneity of sample quality, we introduced a value describing the specific toxicity of ABT-737 related to the background rate of toxicity exerted by ABT-CTRL that is referred to as '% nonspecific toxicity' in Figures 4e and f. A low value indicates high specific toxicity. It ranged from 1.1 to 9.6 for the AML samples tested. No difference in apoptosis induction between bone marrow (BM) and peripheral blood (PB) specimens could be observed in one sample (AML #6).
PBMNCs from three healthy donors served as negative controls for the experiments. The samples showed higher IC 50 values for ABT-737 and the value of nonspecific toxicity ranged from 8.5 to 13.1. As summarized in Figure 4d , ABT-737 was significantly more effective in AML samples compared to healthy donor samples (P ¼ 0.011).
To assess the toxicity of ABT-737 on normal lymphocytes, we also tested PBMNC that were cultured for 4 days in the presence of PHA leading to the expansion of T cells. The majority of cells derived from PHA stimulation consisted in activated Tlymphocytes (60.1% were found positive for CD3 and CD38 surface expression, data not shown) and these cells were found to be resistant up to very high concentrations of ABT-737 (Figures 4c and 5a) . To identify the underlying mechanism for their resistance, we tested these cells for the expression of MCL1 that can protect cells from induction of apoptosis by ABT-737 (Figure 3b) as already reported elsewhere. [26] [27] [28] [29] Intriguingly, PHA-stimulated PBMNCs showed a high level of MCL1 that was comparable to the protein expression in K-562 cells that served as a positive control (MCL1 L , Figures 5b and c) . Transcriptional and translational control of MCL1 expression is characterized by a short half-life at the level of mRNA and protein. Degradation of MCL1 protein is catalyzed by the specific E3 ubiquitin ligase MULE. 30 Treatment of HL-60 cells with the proteasome inhibitor MG-132 resulted in the upregulation of full-length MCL1 protein, whereas degraded MCL1 with smaller molecular weight ABT-737 neutralizes resistance to FLT3 inhibitor treatment in primary AML samples TM Kohl et al was absent (data not shown). Accordingly, we could detect a distinct signal of degraded MCL1 of about 32 kDa (MCL1 S ) in HL-60 cells and AML patient samples (Figures 5b  and c) . The expression level of MCL1 in primary samples in comparison to positive and negative control cell lines is summarized in Figure 5c . As recently reported by Konopleva et al., 28 MCL1 constitutes a critical element in the sensitivity of AML cells to ABT-737. The same observation was made in our study, since the two patient samples with the highest MCL1 content (AML #11 and 13) showed the lowest specific toxicity of ABT-737 (Figure 4e ). Apart from MCL1 expression, there might be some other resistance factors against ABT-737 as well, because PBMNCs that are less sensitive to this compound (Figures 4e and 5a) do not show an elevated MCL1 expression (Figure 5c ).
BCL2 inhibition synergizes with FLT3 inhibitor treatment in AML cell lines and primary AML samples
We could show that BCL2 was expressed independently of the activation status of FLT3 receptor in cells from primary AML samples (Figure 1a) . Thus, we reasoned that combined BCL2 inhibition and FLT3 dephosphorylation resulted in over-additive cytotoxicity in cells with both FLT3 mutation and overexpression of BCL2. The hypothesis was verified in MV4-11 and MOLM-13 cells (Figures 6a and b) . Both cell lines were treated with increasing concentrations of SU5614 in presence or absence of a very low dose of ABT-737 (0.01 mM), which did not induce cytotoxicity by itself. For both cell lines we could demonstrate synergism of FLT3 and BCL2 inhibition as assessed by two-sided paired t-test (Po0.05). The possible cause for the observed synergism might reside in the upregulation of BIM Figure 4 ABT-737 induces apoptotic cell death in primary AML samples (a) and (c). Cells derived from AML patient sample #1 or #2, respectively, were treated for 24 h in the presence or absence of the indicated concentrations of ABT-737 and ABT-CTRL. ABT-737 treatment induced apoptotic cell death with high efficiency in the submicromolar range. (b) and (d) Representative dot plots for Annexin V-PE and 7-AAD staining in treated or untreated AML patient cells (AML #1 or #2, respectively). (e) Effects of ABT-737 and ABT-CTRL are summarized with respect to sample type (PB, peripheral blood sample; BM, bone marrow sample; PHA, PHA stimulation), viability of cells after culture for 24 h in the absence of inhibitor (%), IC 50 values for ABT-737 or ABT-CTRL and nonspecific activity (%). Asterisk (*) indicates that cells were tested in proliferation assays. In these assays, the observed increase in cell number after 72 h was about 1.5 to 2-fold. N/A, not available, n.d., not determined. (f) % Nonspecific activity of ABT-737 was determined for AML samples or PBMNC of healthy donors. The IC 50 value of ABT-737 treatment was related to the IC 50 of the lossof-function control ABT-CTRL and is displayed in percent (%). The difference between AML samples and healthy PBMNC was statistically significant. Mean values are indicated by horizontal lines.
ABT-737 neutralizes resistance to FLT3 inhibitor treatment in primary AML samples TM Kohl et al protein by receptor tyrosine kinase (RTK) inhibitor treatment that has already been described to mediate killing by imatinib 31 and gefitinib. 32 As shown in Figure 6c , FLT3 inhibition for 24 h efficiently induced the upregulation of BIM isoforms in MOLM-13 cells. Recently, Del Gaizo Moore et al. 33 have described the critical role of BIM-BCL2 complexes in the response to ABT-737.
To confirm these findings in primary cells, AML patient samples were treated with increasing doses of FLT3 inhibitor SU5614 or the more water-soluble derivative Sunitinib maleate (Sunitinib), 34 respectively, for 72 h in combination with fixed doses of ABT-737 (0, 0.01 or 0.025, respectively) for 48 h. Representative results are shown in Figures 6d-f . Combined FLT3 and BCL2 inhibition resulted in synergism in all samples tested that were positive for activating FLT3 mutations (Figures 6d,  e and g ). These results were confirmed by clonogenic assays in AML samples #11 and #12 (data not shown). Conversely, sample #13 expressing FLT3-WT receptor as confirmed by FACS analysis using CD135 antibody did not respond to FLT3 inhibition, so that the obtained growth curves shifted only vertically with respect to response to ABT-737 alone ( Figure 6f ). As shown in Figure 6e , treatment with the novel FLT3 inhibitor Sunitinib which is already in phase I clinical trials 35, 36 in combination with very low doses of ABT-737 was able to induce almost complete cell death in AML patient cells with mutant FLT3.
Ci values were calculated according to Chou and Talay 37 and are summarized in Figure 6g .
Discussion
In contrast to CML, AML defines a very heterogeneous disease with resistance to chemotherapeutic agents and specific inhibitors, for example inhibitors directed against FLT3 receptor tyrosine kinase. In this study, we identified the BCL2 oncoprotein as a major target in hematological malignancies that is not only of importance for B cell lymphomas and chronic lymphocytic leukemia (CLL) with t(14;18) or other genetic lesions affecting the BCL2 gene, but also for the pathogenesis of AML. High expression of BCL2 was shown in all AML tested samples in contrast to BCL-xL and MCL1. We could demonstrate that FLT3 dephosphorylation over a long time period is not able to cause downregulation of BCL2 in primary AML samples (Figure 1a) , so that mutated FLT3 is not likely to be the cause for the increase in BCL2 protein levels. This finding is in line with a previous report from Minami et al. 38 showing in 32D cells that expression of FLT3-ITD promotes the upregulation of BCL-xL, but not of BCL2. BCL2 might, therefore, define a major obstacle for the treatment of AML with FLT3 specific inhibitors. One more evidence for the importance of BCL2 in AML is provided by the study of Jaiswal et al. 39 In that report, the authors show that ectopic expression of BCR-ABL in combination with BCL2 does not induce a CML-like phenotype, but AML. This finding points to an essential role of BCL2 in the pathogenesis of AML. We found that ABT-737 induced apoptotic cell death at very low concentrations in the submicromolar range in primary AML cells and AML cell lines. Conversely, a recent study demonstrated the efficacy of BCL2 and BCL-xL inhibition in multiple myeloma cells, but the IC 50 values ranged from 2 to 10 mM. 40 The mechanisms of BCL2 overexpression in AML remain unknown but might be, in part, due to the perturbed activity of microRNAs (miRNAs). 41, 42 MiRNAs miR-15 and miR-16 have been shown to be downregulated in the majority of CLLs, 43 but also in a subset of AML samples. 44 The fusion gene AML1-ETO encoding for a transcription factor with disturbed activity has been shown to induce BCL2. 45 In Kasumi-1 cells carrying the translocation 8;21 we could show expression of BCL2, but at lower levels than in the other AML cell lines tested. Kasumi-1 cells, however, responded efficiently to BCL2 inhibition by ABT-737 (Figure 3a) . In contrast to the AML cell lines, we could detect a high expression of MCL1 protein in all cell lines transformed by BCR-ABL. This finding is in line with the report by Aichberger et al. demonstrating that BCR-ABL causes enhancement of MCL1 promoter activity. 23 Conversely, BCL2 seems to be dispensable for these cells because K-562 cells are negative for BCL2 expression and KCL-22 as well as SD-1 cell lines contain a reduced amount of BCL2 (Figure 3b) . Interestingly, stable expression of BCR-ABL in HL-60 was reported to induce substantial downregulation of BCL2 and upregulation of BCL-xL. 46 Furthermore, a recent study describes a cell line model in which the authors studied the mechanisms underlying the resistance to small molecule inhibitor imatinib that is used in the therapy of CML. 47 Compared to the parental K-562 and LAMA cell lines, imatinib-resistant clones showed a strong increase in BCL2 expression and a reduced expression of BCR-ABL and BCL-xL. Downregulation of BCL2 by anti-sense strategies restored the ability of imatinib to trigger cell death in the resistant clones.
In contrast to AML cell lines, BCR-ABL transformed cells showed high protein levels of MCL1 and BCL-xL. These antiapoptotic proteins have redundant functions in prohibiting apoptotic cell death by cytochrome c release from the mitochondria. 48 Displacing BCL-xL from BAX and BAK would not facilitate the induction of apoptosis in these cells, because MCL1 is still able to prevent BAX and BAK oligomerization. ABT-737 neutralizes resistance to FLT3 inhibitor treatment in primary AML samples TM Kohl et al
As predicted by our model, the combined inhibition of FLT3 and BCL2 is likely to induce synergistic effects in AML cells probably via upregulation of the pro-apoptotic protein BIM. We could demonstrate synergism of two different FLT3 inhibitors with ABT-737 in various patient samples and AML cell lines with mutated FLT3, but not with FLT3-WT ( Figure 6 ). Taken together, our study provides evidence that the inhibition of anti-apoptotic proteins, particularly BCL2, might contribute to a successful antileukemic treatment in AML. Furthermore, it might improve the efficiency of other molecular therapeutic principles, such as the inhibition of constitutively activated signaling molecules, for example, FLT3 receptor tyrosine kinase. ABT-737 neutralizes resistance to FLT3 inhibitor treatment in primary AML samples TM Kohl et al
